The Hindu reported that the US-based pharma giants Eli Lilly and company has filed a suit against two Indian drug companies, Lupin, and Aurobindo Pharma alleging infringement of patent (US 5023269) of its anti-depressant drug Cymbalta, generically known as duloxetine HCl.
Filing a petition on November 24, before US District Court for the Southern Districts of Indiana, Eli Lilly and company has alleged that Lupin and its US-based subsidiary Lupin Pharmaceuticals Inc has infringed its inetellcutual property rights granted for anti-depressant drug Cymbalta.
According to the source the US drug giant has also filed complaint against Aurobindo Pharma USA INC, the US arm of Hyderabad-based Indian drug major Aurobindo Pharma.
Cymbalta, an anti-depressant drug whose patent will expire on June, 2013, has a total global sales of around two billion dollars in Eli Lilly's portfolio.
Till now, Eli Lilly and company has filed suits alleging patent infringement against six companies in United States of which three are Indian firms including Wockhardt.
The other three firms against which Eli Lilly and company has alleged patent infringement for its anti-depressant drug Cymbalta in US are Sandoz, Cobalt Laboratories and Impax Laboratories. These six firms against whom Eli Lilly and company has filed suit have actually applied for marketing approval of copy version Cymbalta under an abbreviated new drug application.
No comments:
Post a Comment